Accelerating Breakthrough Discoveries into Medicines

Rama K. Mallampalli, MD

Dr. Mallampalli’s research is focused on developing new therapeutics targeting proteinases involved in inflammatory disorders such as pneumonia and sepsis.

Rama Mallampalli, MD is professor and division chief of pulmonary, allergy, and critical care medicine and UPMC endowed professor at the University of Pittsburgh School of Medicine. He also is director of the Acute Lung Injury (ALI) Center of Excellence at the university.

His research program discovered a unique model for the molecular behavior of ubiquitin E3 ligase subunits belonging to the Skp-Cullin1-F box (SCF) family that control inflammation. Dr. Mallampalli’s laboratory designed, synthesized, and tested the first-in-class genus of ubiquitin E3 ligase (F box) inhibitors that modulate proteolysis thereby inhibiting inflammation in preclinical models of ALI and multi-organ failure.

Dr. Mallampalli aims to optimize and assess efficacy of a lead compound that inhibits an F box protein that is involved in acute cellular rejection during lung transplantation. Acute cellular rejection is the predominant risk factor for chronic allograft rejection or bronchiolitis obliterans syndrome. This work is important because a major obstacle for long-term success after lung transplantation is chronic allograft rejection, the major factor contributing to allograft loss and death. Dr. Mallampalli received his medical degree at the University of Wisconsin and completed his residency training at Hennepin County Medical Center in Minneapolis prior to his fellowship in Pulmonary and Critical Care Medicine at the University of Iowa.

Dr. Mallampalli has had or currently holds editorial appointments with several journals including the Journal of Biological Chemistry, the American Journal of Physiology, and the American Journal of Respiratory and Critical Care Medicine. He also serves on multiple peer review panels including the LIRR Study Section and Program Project Grant applications for the NIH. He is an elected member of the Association of American Physicians and the American Society of Clinical Investigation, an Established Investigator of the American Heart Association, and a Career Investigator of the American Lung Association.

Dates to Know

April 5, 2017
Letter of Intent Deadline

May 31, 2017
Full Application Deadline (For those invited)

December 2017
Awardees Notified

Harrington Project

The Harrington Discovery Institute is the nonprofit arm of the Harrington Project for Discovery & Development, an international initiative supporting breakthrough research by physician-scientists. The Project is a new and powerful approach to address some of the challenges hindering advancement of medicine today.

The Harrington Grant is an important part of the overall pharmaceutical research initiative created by The Harrington Project.

For Questions

For questions about the Scholar-Innovator grants or the application process, please email